Advanced Therapies in IBD: Biologics and Beyond (IASGO 2026) - Sep 23, 2026 - Abstract #IBD-3; Pres time: Sep 11, 2026; 08:00 AM - 09:00 AM; "Ulcerative colitis: For moderate-to-severe UC, biologic options include anti-TNF agents (infliximab, adalimumab,and golimumab), vedolizumab, ustekinumab, and selective IL-23 inhibitors (mirikizumab,risankizumab, and guselkumab). Small-molecule therapies, including JAK inhibitors (tofacitiniband upadacitinib) and S1P receptor modulators (ozanimod and etrasimod), further expandtherapeutic options...Recent AGA guidance further incorporates newer IL-23inhibitors, including mirikizumab and guselkumab, and upadacitinib into the expandingtherapeutic armamentarium. Overall, contemporary IBD management is shifting from rigid treatment algorithms toward early,individualized selection of advanced therapies, integrating efficacy, safety, disease phenotype, priortreatment exposure, and patient preference."
Metastases • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A
|